source
- Astellas therapy brings new hope to rare disease patients amid broader biotech challengesA new Astellas treatment is being highlighted as a source of optimism for a community affected by a rare disease, after a period of setbacks in the program. The article also notes a revived gene t…
- Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial resultsBraveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…